APA (7th ed.) Citation

Ding, L., Nuersulitan, R., Wang, J., Chen, H., & Zhuo, M. (2026). Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression. Current Oncology, 33(5), 258. https://doi.org/10.3390/curroncol33050258

Chicago Style (17th ed.) Citation

Ding, Lu, Reyizha Nuersulitan, Jingjing Wang, Hanxiao Chen, and Minglei Zhuo. "Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression." Current Oncology 33, no. 5 (2026): 258. https://doi.org/10.3390/curroncol33050258.

MLA (9th ed.) Citation

Ding, Lu, et al. "Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression." Current Oncology, vol. 33, no. 5, 2026, p. 258, https://doi.org/10.3390/curroncol33050258.